IHI ILLUMINATE project

ILLUMINATE is a collaborative research program which aims to demonstrate the unique value of Metabolic Magnetic Resonance Imaging (MeMRI), used to visualize chemical processes in the body, to significantly improve effective application of theranostics - an approach combining diagnosis, treatment, and continuous follow up of a condition. ILLUMINATE will provide the first clinical translation of MeMRI, with application to castrate resistant metastatic prostate cancer. This will pave the way for future expansion of the technology for use in earlier cancer stages and in other cancer types. In parallel, ILLUMINATE seeks to increase the overall availability of lutetium - a highly promising targeted radioligand therapy recently approved for metastasized prostate cancer, and develop more sustainable production methods for it. ILLUMINATE is a four-and-a-half-year public-private partnership, funded by the Innovative Health Initiative (IHI). Among ILLUMINATE’s partners are MedTech companies, research institutes, university hospitals and small- and medium-sized enterprises. ILLUMINATE’s partners are: UMC Utrecht, Euro-Bioimaging ERIC, Philips Medical Systems Nederland BV, Philips Gmbh Innovative Technologies, Synlab Sdn Spa, Consiglio Nazionale Delle Ricerche, University of Turin, Bracco Imaging Spa, Tesla Dynamic Coils BV, Wavetronica BV, Lund University, Nuclear Research & Consultancy Group, Amsterdam UMC, University Hospital Essen, Lygature. The consortium is coordinated by UMC Utrecht, together with NRG PALLAS as a project lead. Acknowledgement of support This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101172722. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.